Cargando…

Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer

Adjuvant therapy for patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer (EBC) remains challenging. The prognostic significance of HER2-low positivity in these patients is not fully understood. In our retrospectiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Shikata, Shohei, Murata, Takeshi, Yoshida, Masayuki, Hashiguchi, Hiromi, Yoshii, Yukiko, Ogawa, Ayumi, Watase, Chikashi, Shiino, Sho, Sugino, Hirokazu, Jimbo, Kenjiro, Maeshima, Akiko, Iwamoto, Eriko, Takayama, Shin, Suto, Akihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640570/
https://www.ncbi.nlm.nih.gov/pubmed/37952045
http://dx.doi.org/10.1038/s41598-023-47033-8
_version_ 1785133784591499264
author Shikata, Shohei
Murata, Takeshi
Yoshida, Masayuki
Hashiguchi, Hiromi
Yoshii, Yukiko
Ogawa, Ayumi
Watase, Chikashi
Shiino, Sho
Sugino, Hirokazu
Jimbo, Kenjiro
Maeshima, Akiko
Iwamoto, Eriko
Takayama, Shin
Suto, Akihiko
author_facet Shikata, Shohei
Murata, Takeshi
Yoshida, Masayuki
Hashiguchi, Hiromi
Yoshii, Yukiko
Ogawa, Ayumi
Watase, Chikashi
Shiino, Sho
Sugino, Hirokazu
Jimbo, Kenjiro
Maeshima, Akiko
Iwamoto, Eriko
Takayama, Shin
Suto, Akihiko
author_sort Shikata, Shohei
collection PubMed
description Adjuvant therapy for patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer (EBC) remains challenging. The prognostic significance of HER2-low positivity in these patients is not fully understood. In our retrospective study, we analyzed 647 patients with HR-positive, HER2-negative, node-positive EBC, stratifying them into three cohorts based on axillary lymph node involvement, tumor size, and characteristics. Cohort 1 included patients with either ≥ 4 positive axillary lymph nodes or 1–3 positive nodes with histological grade 3 or tumor size ≥ 5 cm. Cohort 2 consisted of patients with 1–3 positive nodes, histological grade < 3, tumor size < 5 cm, and Ki-67 ≥ 20%. Cohort 3 comprised patients with 1–3 positive nodes, histological grade < 3, tumor size < 5 cm, and Ki-67 < 20%. We compared invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS) between HER2-low (IHC1+ or IHC2+/FISH−) and HER2-zero (IHC0) groups in each cohort. In cohort 1, HER2-low patients exhibited significantly better 5-year IDFS (84.2% vs. 73.6%, p = 0.0213) and DRFS (88.2% vs. 79.8%, p = 0.0154). However, no significant differences were observed in cohorts 2 and 3. Our findings suggest HER2-low positivity as a prognostic factor in HR-positive, HER2-negative, and node-positive EBC.
format Online
Article
Text
id pubmed-10640570
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-106405702023-11-11 Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer Shikata, Shohei Murata, Takeshi Yoshida, Masayuki Hashiguchi, Hiromi Yoshii, Yukiko Ogawa, Ayumi Watase, Chikashi Shiino, Sho Sugino, Hirokazu Jimbo, Kenjiro Maeshima, Akiko Iwamoto, Eriko Takayama, Shin Suto, Akihiko Sci Rep Article Adjuvant therapy for patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer (EBC) remains challenging. The prognostic significance of HER2-low positivity in these patients is not fully understood. In our retrospective study, we analyzed 647 patients with HR-positive, HER2-negative, node-positive EBC, stratifying them into three cohorts based on axillary lymph node involvement, tumor size, and characteristics. Cohort 1 included patients with either ≥ 4 positive axillary lymph nodes or 1–3 positive nodes with histological grade 3 or tumor size ≥ 5 cm. Cohort 2 consisted of patients with 1–3 positive nodes, histological grade < 3, tumor size < 5 cm, and Ki-67 ≥ 20%. Cohort 3 comprised patients with 1–3 positive nodes, histological grade < 3, tumor size < 5 cm, and Ki-67 < 20%. We compared invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS) between HER2-low (IHC1+ or IHC2+/FISH−) and HER2-zero (IHC0) groups in each cohort. In cohort 1, HER2-low patients exhibited significantly better 5-year IDFS (84.2% vs. 73.6%, p = 0.0213) and DRFS (88.2% vs. 79.8%, p = 0.0154). However, no significant differences were observed in cohorts 2 and 3. Our findings suggest HER2-low positivity as a prognostic factor in HR-positive, HER2-negative, and node-positive EBC. Nature Publishing Group UK 2023-11-11 /pmc/articles/PMC10640570/ /pubmed/37952045 http://dx.doi.org/10.1038/s41598-023-47033-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Shikata, Shohei
Murata, Takeshi
Yoshida, Masayuki
Hashiguchi, Hiromi
Yoshii, Yukiko
Ogawa, Ayumi
Watase, Chikashi
Shiino, Sho
Sugino, Hirokazu
Jimbo, Kenjiro
Maeshima, Akiko
Iwamoto, Eriko
Takayama, Shin
Suto, Akihiko
Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer
title Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer
title_full Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer
title_fullStr Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer
title_full_unstemmed Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer
title_short Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer
title_sort prognostic impact of her2-low positivity in patients with hr-positive, her2-negative, node-positive early breast cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640570/
https://www.ncbi.nlm.nih.gov/pubmed/37952045
http://dx.doi.org/10.1038/s41598-023-47033-8
work_keys_str_mv AT shikatashohei prognosticimpactofher2lowpositivityinpatientswithhrpositiveher2negativenodepositiveearlybreastcancer
AT muratatakeshi prognosticimpactofher2lowpositivityinpatientswithhrpositiveher2negativenodepositiveearlybreastcancer
AT yoshidamasayuki prognosticimpactofher2lowpositivityinpatientswithhrpositiveher2negativenodepositiveearlybreastcancer
AT hashiguchihiromi prognosticimpactofher2lowpositivityinpatientswithhrpositiveher2negativenodepositiveearlybreastcancer
AT yoshiiyukiko prognosticimpactofher2lowpositivityinpatientswithhrpositiveher2negativenodepositiveearlybreastcancer
AT ogawaayumi prognosticimpactofher2lowpositivityinpatientswithhrpositiveher2negativenodepositiveearlybreastcancer
AT watasechikashi prognosticimpactofher2lowpositivityinpatientswithhrpositiveher2negativenodepositiveearlybreastcancer
AT shiinosho prognosticimpactofher2lowpositivityinpatientswithhrpositiveher2negativenodepositiveearlybreastcancer
AT suginohirokazu prognosticimpactofher2lowpositivityinpatientswithhrpositiveher2negativenodepositiveearlybreastcancer
AT jimbokenjiro prognosticimpactofher2lowpositivityinpatientswithhrpositiveher2negativenodepositiveearlybreastcancer
AT maeshimaakiko prognosticimpactofher2lowpositivityinpatientswithhrpositiveher2negativenodepositiveearlybreastcancer
AT iwamotoeriko prognosticimpactofher2lowpositivityinpatientswithhrpositiveher2negativenodepositiveearlybreastcancer
AT takayamashin prognosticimpactofher2lowpositivityinpatientswithhrpositiveher2negativenodepositiveearlybreastcancer
AT sutoakihiko prognosticimpactofher2lowpositivityinpatientswithhrpositiveher2negativenodepositiveearlybreastcancer